The Amgen Tour of California is the biggest cycling event on U.S. soil and it’s definitely one of the most important races of the season for Team Novo Nordisk, so we are excited to introduce our new U.S. kit at this prestigious race.
Atlanta, Ga. (PRWEB) May 12, 2016
Team Novo Nordisk, the world’s first all-diabetes professional cycling team, will reveal a new U.S. kit at the Amgen Tour of California, an eight-day stage race covering nearly 800 miles of California terrain that begins Sunday, May 15. Eight riders from Team Novo Nordisk will wear the new green kit featuring a Tresiba® (insulin degludec injection 200 Units/mL) logo for the first time when they line up at the start in San Diego, California. The kit will be worn at U.S. races only.
“The Amgen Tour of California is the biggest cycling event on U.S. soil and it’s definitely one of the most important races of the season for Team Novo Nordisk, so we are excited to introduce our new U.S. kit at this prestigious race,” said Phil Southerland, co-founder & CEO of Team Novo Nordisk. “This year marks our third consecutive appearance at the Amgen Tour of California, and we are eager to use this opportunity to show the 415 million people around the world living with diabetes what may be possible.”
The Amgen Tour of California serves as Team Novo Nordisk’s first major U.S. race of the season. In 2014, Charles Planet (FRA) wore the race’s Breakaway from Cancer Most Courageous Rider jersey in Stages 2 and 3, while teammate Kevin De Mesmaeker (BEL) sprinted to third place on Stage 4. Over the past two editions, Team Novo Nordisk athletes earned three top-10 finishes and rode in major breakaways on five separate stages.
Team Novo Nordisk is a global team made up of nearly 100 endurance athletes with diabetes, including cyclists, runners and triathletes. The men’s professional cycling team includes 17 athletes from nine countries.
Tresiba® is a long-acting insulin that is manufactured by Novo Nordisk. For more information, go to http://www.tresiba.com.
Tresiba® is a long-acting insulin that lasts at least 42 hours after the last of eight once-daily injections (0.4 U/kg), and has a consistently flat and stable profile at steady state.¹⁻³ Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® should take their dose as soon as they remember, then continue with their regular dosing schedule, making sure there are at least eight hours between doses.¹ Tresiba® is available in Novo Nordisk’s latest insulin delivery device – FlexTouch® – as a 100 units/mL or 200 units/mL pen. Tresiba® U-200 FlexTouch® can dose up to 160 units in a single injection.¹ FlexTouch® is also the only prefilled insulin pen with no push-button extension.¹
What is Tresiba®?
- Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults with diabetes
- Tresiba® is not for people with diabetic ketoacidosis
- Tresiba® is available in 2 concentrations: 200 units/mL and 100 units/mL
- It is not known if Tresiba® is safe and effective in children under 18 years of age
Important Safety Information
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Who should not take Tresiba®?
Do not take Tresiba® if you:
- are having an episode of low blood sugar
- are allergic to Tresiba® or any of the ingredients in Tresiba®
Before taking Tresiba®, tell your health care provider about all of your medical conditions, including if you are:
- pregnant, planning to become pregnant, or are breastfeeding
- taking new prescription or over-the-counter medicines, vitamins, or herbal supplements
Talk to your health care provider about low blood sugar and how to manage it.
How should I take Tresiba®?
- Read the Instructions for Use and take Tresiba® exactly as your health care provider tells you to
- Do not do any conversion of your dose. The dose counter always shows the selected dose in units
- Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to
- If you miss or are delayed in taking your dose of Tresiba®:
-- Take your dose as soon as you remember, then continue with your regular dosing schedule
-- Make sure there are at least 8 hours between doses
- Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them
- Do not reuse or share your needles with other people. You may give them a serious infection, or get a serious infection from them
- Never inject Tresiba® into a vein or muscle
- Never use a syringe to remove Tresiba® from the FlexTouch® pen
What should I avoid while taking Tresiba®?
- Do not drive or operate heavy machinery, until you know how Tresiba® affects you
- Do not drink alcohol or use prescription or over-the-counter medicines that contain alcohol
What are the possible side effects of Tresiba®?
Tresiba® may cause serious side effects that can be life-threatening, including:
- Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache
- Low potassium in your blood (hypokalemia)
- Heart failure in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Tresiba®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain
Your insulin dose may need to change because of a change in the level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Common side effects may include reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please click here for Prescribing Information.
In the United States, more than 29 million people are affected by diabetes.⁴ Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.⁴ Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has almost quadrupled over the past 30 years.⁵
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With its U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has more than 5,000 employees in the United States. For more information, visit novonordisk-us.com or follow us on Twitter: @novonordiskus.
About Team Novo Nordisk
Team Novo Nordisk is the world’s first all-diabetes UCI Professional Continental cycling team. In 2012, Phil Southerland, co-founder and CEO of the team, and global healthcare company Novo Nordisk came together to create Team Novo Nordisk, based on a shared vision to inspire, educate and empower people around the world affected by diabetes. For more information, visit http://www.teamnovonordisk.com.
1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2015.
2. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Diabetes Obes Metab. 2012;14(9):859-864.
3. Heise T, Korsatko S, Nosek L, et al. J Diabetes. 2016;8(1):132-138.
4. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. CDC website. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed April 19, 2016.
5. Centers for Disease Control and Prevention. Number (in Millions) of Civilian, Noninstitutionalized Adults with Diagnosed Diabetes, United States, 1980–2014. CDC website. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed April 19, 2016.
FlexTouch® and Tresiba® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2016 Novo Nordisk All rights reserved. USA16TSM02297 May 2016